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SUMMARY
The IkB kinase (IKK) subunit NEMO/IKKg is essential for activation of the transcription factor NF-kB,
which regulates cellular responses to inflammation. The function of NEMO in the adult liver remains
elusive. Here we show that ablation of NEMO in liver parenchymal cells caused the spontaneous
development of hepatocellular carcinoma inmice. Tumor developmentwas precededby chronic liver
disease resembling human nonalcoholic steatohepatitis (NASH). Antioxidant treatment and genetic
ablation of FADD demonstrated that death receptor-mediated and oxidative stress-dependent death
of NEMO-deficient hepatocytes triggered disease pathogenesis in this model. These results reveal
that NEMO-mediated NF-kB activation in hepatocytes has an essential physiological function to
prevent the spontaneous development of steatohepatitis and hepatocellular carcinoma, identifying
NEMO as a tumor suppressor in the liver.INTRODUCTION
The nuclear factor (NF)-kB signaling pathway mediates
a variety of important cellular functions by regulating im-
mune and inflammatory responses (Karin and Lin, 2002;
Pahl, 1999). NF-kB transcription factors are kept inactive
in the cytoplasm through binding to members of the IkB
family of inhibitory proteins. Cell activation by a variety of
stimuli induces the phosphorylation, polyubiquitination,
and proteasome-dependent degradation of IkB proteins,
allowing NF-kB dimers to accumulate in the nucleus
(Karin and Lin, 2002; Pahl, 1999). The IkB kinase (IKK)
complex, consisting of two catalytic subunits—IKK1/
IKKa and IKK2/IKKb—and a regulatory subunit calledCanNF-kB-essential-modulator (NEMO/IKKg), mediates NF-
kB activation in response to a variety of stimuli by phos-
phorylating IkB proteins (Ghosh and Karin, 2002; Karin,
1999). Gene-targeting experiments showed that mice
lacking p65/RelA, IKK2, or NEMO die during embryonic
development due to liver apoptosis (Beg et al., 1995; Li
et al., 1999a, 1999b; Tanaka et al., 1999; Rudolph et al.,
2000; Schmidt-Supprian et al., 2000; Makris et al., 2000).
Although these studies demonstrated the essential role
of NF-kB in protecting the fetal liver from cell death, the
physiological function of NF-kB in the adult liver remains
elusive. Despite various attempts to address the function
of NF-kB in the adult liver, previous studies failed to reveal
a spontaneous phenotype caused by NF-kB inhibition inSIGNIFICANCE
NF-kB is constitutively activated in many tumors and is thought to provide a critical survival signal that assists
cancer cells to escape apoptosis. Thus, NF-kB inhibition is considered a promising approach in antitumor therapy.
Our results presented here show that sensitization of hepatocytes to apoptosis by NF-kB inhibition causes stea-
tohepatitis and hepatocellular carcinoma, providing a paradigm for the role of NF-kB in cancer. In addition, these
findings suggest that NF-kBmight provide amolecular link connecting inflammatory, survival, andmetabolic path-
ways in the liver andmay be relevant for the pathogenicmechanisms linkingNASH to liver cancer in humans. These
results highlight the need for extensive research on the potential side effects of drugs targeting the IKK/NF-kB
pathway.cer Cell 11, 119–132, February 2007 ª2007 Elsevier Inc. 119
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transgenic overexpression of IkBa-super-repressors (Lavon
et al., 2000; Chaisson et al., 2002; Maeda et al., 2003,
2005; Pikarsky et al., 2004; Luedde et al., 2005), suggest-
ing that NF-kB is not essential for normal liver physiology.
Hepatocellular carcinoma is one of the most common
cancers worldwide and develops frequently in the context
of chronic hepatitis characterized by liver inflammation
and hepatocyte apoptosis (Motola-Kuba et al., 2006;
Okuda, 2000). However, the molecular mechanisms un-
derlying this sequence of events are only poorly under-
stood. Recently, the function of NF-kB signaling in the
development of liver tumors has raised great interest. In
one study, NF-kB inhibition by overexpression of a nonde-
gradable IkBa super-repressor was shown to inhibit later
stages of tumor progression in Mdr2-deficient mice, which
develop hepatocellular carcinoma in the context of chronic
bile duct inflammation (Pikarsky et al., 2004). On the other
hand, deletion of Ikk2 in hepatocytes resulted in increased
tumor formation in a mouse model of chemical carcino-
gen-induced hepatocellular carcinomas (Maeda et al.,
2005). These apparently contradicting conclusions may
be influenced by differences in the inhibitory potential
and the cell specificity of the methods used to block
NF-kB, and also by the different tumor models applied.
Therefore, the function of NF-kB in liver cancer seems to
be complex, acting either as a tumor promoter or as
a tumor suppressor.
Here we have investigated the function of the IKK sub-
unit NEMO in liver physiology by generating mice with
conditional ablation of NEMO in parenchymal liver cells.
Ablation of NEMO but not IKK2 caused the spontaneous
development of liver cancer, revealing a role of NEMO
as a tumor suppressor in the liver. We show that tumor
formation is preceded by the spontaneous development
of chronic hepatitis resembling human nonalcoholic
steatohepatitis (NASH). This process is initiated by the
hypersensitivity of NEMO-deficient hepatocytes to spon-
taneous FADD-mediated and oxidative-stress-depen-
dent death, which triggers compensatory hepatocyte
proliferation, inflammation, and activation of liver progen-
itor cells. These results demonstrate that NEMO-depen-
dent NF-kB activation has an essential physiological
function to prevent spontaneous liver tumor develop-
ment.
RESULTS
Spontaneous Development of Hepatocellular
Carcinomas in NEMOLPC-KO Mice
Mice lacking NEMO die during embryonic development
(Rudolph et al., 2000; Schmidt-Supprian et al., 2000;
Makris et al., 2000). To investigate the role of NEMO
and IKK2 in the adult liver, we generated mice with liver
parenchymal cell-specific knockout of these subunits
(NEMOLPC-KO, IKK2LPC-KO) by crossing mice carrying
loxP-flanked Nemo (Schmidt-Supprian et al., 2000) or
Ikk2 (Pasparakis et al., 2002) alleles with Alfp-cre trans-
genics, which mediate efficient Cre recombination in liver120 Cancer Cell 11, 119–132, February 2007 ª2007 Elsevier Incparenchymal cells, including hepatocytes and biliary epi-
thelial cells, but not in endothelial or Kupffer cells (Coffin-
ier et al., 2002; Kellendonk et al., 2000). NEMOLPC-KO mice
were born and reached weaning age at the expected
Mendelian frequency. NEMOLPC-KO mice and IKK2LPC-KO
mice showed efficient ablation of the respective pro-
teins in whole-liver extracts (Figure 1A). Low residual
expression of NEMO and IKK2 in these mice can be attri-
buted to nonparenchymal liver cells that are not targeted
by the Alfp-cre construct. Accordingly, primary hepato-
cytes isolated from NEMOLPC-KO and IKK2LPC-KO mice
showed complete lack of NEMO and IKK2, respectively
(Figure 1B).
Dissection of livers from 12-month-old male NEMOLPC-KO
mice surprisingly revealed the presence of multiple
large tumors (Figures 1C and 1D). No tumors were de-
tected either in the liver of littermates carrying the NEMO
loxP flanked allele but lacking Cre recombinase expres-
sion (Figure 1E), which were used as wild-type controls
in all experiments described here, or in IKK2LPC-KO mice
at the same age (Figure 1F). Histological analysis revealed
the presence of malignant liver tumors corresponding to
well- to moderately differentiated hepatocellular carcino-
mas (Figures 1I–1N), as well as premalignant liver tumors
(dysplastic foci, low-grade and high-grade dysplastic
nodules; Figure 1H). Malignant liver tumors, as defined
histologically by the International Working Party (1995)
(Kojiro and Roskams, 2005), were detected in all 14
male mice examined at this age. The average number of
malignant liver tumors per mouse was 5.75 (standard de-
viation [SD] = 3.09) with an average size of 8.58 mm (SD =
3.01 mm). Malignant liver tumors were characterized by
expansive growth (Figures 1I–1K), increased cellularity,
a broad trabecular growth pattern in four to six layers,
increased eosinophilia, a higher nuclear to cytoplasmic
index compared to hepatocytes in nontumor areas (com-
pare Figure 1L [HCC] to Figure 1M [nonmalignant]), and
complete absence of portal tracts even within large tumor
areas (Figures 1I–1K). Moreover, malignant liver tumors
displayed a strongly increased proliferation as shown by
increased BrdU incorporation (Figure S1 in the Supple-
mental Data available with this article online) and by
counting mitotic figures (average of 1.44 mitotic figures
per high-power field [hpf] with a range between 1.13 and
2.79 mitotic figures per hpf in different tumors, compared
to 0.13 mitotic figures per hpf in nonmalignant areas)
(Figure 1N). In livers from NEMOLPC-KO mice at 9 months
of age, dysplastic foci and nodules but no malignant
tumors were found (data not shown), suggesting that ma-
lignant tumors arise between 9 and 12 months of age. To
verify deletion of NEMO in malignant liver tumors in
NEMOLPC-KO mice, we performed immunoblot and immu-
nofluorescence analyses on dissected tumor tissue and
found that tumors lack NEMO expression (Figure S2).
Taken together, these results demonstrate that condi-
tional deletion of Nemo but not Ikk2 in parenchymal liver
cells results in spontaneous development of hepatocellu-
lar carcinomas in mice, revealing a function of NEMO as
a tumor suppressor in the liver..
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Liver Tumors in NEMOLPC-KO Mice
(A) Liver extracts from 8-week-old NEMOLPC-KO
mice and littermate control mice (WT) (left
panel) or IKK2LPC-KO and WT mice (right panel)
were analyzed by immunoblot with the indi-
cated antibodies. Tubulin served as loading
control.
(B) Protein extracts from primary hepatocytes
isolated from NEMOLPC-KO, IKK2LPC-KO, and
control mice were analyzed by immunoblot
with the indicated antibodies.
(C and D) Macroscopic appearance of livers of
NEMOLPC-KO mice at 12 months of age. Arrows
indicate large tumors.
(E and F) Normal macroscopic appearance of
representative livers from a 12-month-old WT
mouse (E) and IKK2LPC-KO mouse (F).
(G–N) Representative hematoxylin/eosin (H/E)-
stained liver sections showing normal histolog-
ical architecture in a control mouse (G) and liver
tumors in 12-month-old NEMOLPC-KO mice
(H–N). LGDN, low-grade dysplastic nodule;
HGDN, high-grade dysplastic nodule (H).
HCC, hepatocellular carcinoma (I–L and N).
Arrows indicate the rims of tumors (I and J).
Blue arrows indicate the rims of an area of
broad trabecular growth of malignant tumor
cells in four to six layers (L). Yellow arrows
mark mitotic figures (N).Spontaneous Liver Tumor Development in
NEMOLPC-KO Mice Is Preceded by Steatohepatitis
Hepatocellular carcinomas in humans frequently arise on
the basis of chronic inflammation, whereas spontaneous
development of malignant liver tumors in otherwise
healthy livers is a rare event (Motola-Kuba et al., 2006;
Okuda, 2000; Sherman, 2005). Therefore, we examined
livers from NEMOLPC-KO, IKK2LPC-KO, and littermate con-
trol mice at different ages to assess whether these mice
develop a liver phenotype already at younger age. Livers
from 6-month-old NEMOLPC-KO mice already displayed
macroscopically visible nodules (Figures 2A–2C). On his-
tological examination, focal areas of lipid accumulation
and a variety of low-grade and high-grade dysplastic nod-
ules with expansive growth were observed in livers from
NEMOLPC-KO mice at this stage (Figures 2D–2F). Further-
more, NEMO-deficient livers showed signs of steatosis
with increased lipid deposition in hepatocytes (Figures
2G–2I), and hepatocyte ballooning (data not shown),Caa characteristic pathological feature seen in human nonal-
coholic steatohepatitis (NASH) (Brunt, 2004).
Livers from 8-week-old NEMOLPC-KO mice already
showed signs of steatohepatitis characterized by immune
cell infiltration into the liver parenchyma (Figures 3A and
3B) and steatosis (Figure 3C). Moreover, hepatocytes dis-
played characteristic features of large-cell dysplasia with
strong anisokaryosis (Figures 3D and 3E), a condition
also seen in chronic liver disease in humans, where it is as-
sociated with an increased risk for development of hepato-
cellular carcinoma (Libbrecht et al., 2001, 2005). Further-
more, Sirius red collagen staining revealed the presence
of fibrosis in the liver of NEMOLPC-KO mice (Figure S3), re-
sembling the consequences of chronic inflammation and
NASH in humans (Farrell and Larter, 2006) and also repre-
senting a risk factor for the development of hepatocellular
carcinoma (Sherman, 2005). In contrast, mice lacking the
IKK2 subunit in hepatocytes did not show histopathologi-
cal alterations (Figure 3F). Therefore, conditional knockoutncer Cell 11, 119–132, February 2007 ª2007 Elsevier Inc. 121
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NASH in 6-Month-Old NEMOLPC-KO Mice
(A–C) Livers from 6-month-old control (A) and
IKK2LPC-KO mice are normal (C), while livers
from NEMOLPC-KO mice show macroscopically
visible nodules (indicated by arrows) (B).
(D–F) Representative H/E-stained liver sections
showing dysplastic nodules with vacuoles of
accumulated fat in NEMOLPC-KO (E and F) but
not in control mice (D). Arrows indicate the rim
of an expansively growing dysplastic nodule
in (F).
(G–I) Representative oil-red-O-stained histolog-
ical sections showing accumulation of lipids in
NEMOLPC-KO mice (H), but not in control (G) or
IKK2LPC-KO mice (I).of NEMO in liver parenchymal cells leads to the spontane-
ous development of chronic hepatitis, steatosis, liver fibro-
sis, and HCC, a phenotype that resembles closely the
sequence of events seen in human patients with nonalco-
holic fatty liver disease (NAFLD) and NASH.
To further examine early stages of NASH development in
NEMOLPC-KO mice, we performed electron microscopy
(EM) analysis on livers from 8-week-old mice. Mitochon-
dria in hepatocytes in NEMO-deficient livers appeared
swollen and displayed a reduction in mitochondrial crests
compared to wild-type control tissue (Figures 3G and 3H),
thus pointing toward a disturbance in mitochondrial
function and oxidative metabolism. Moreover, large areas122 Cancer Cell 11, 119–132, February 2007 ª2007 Elsevier Inof irregularly shaped glycogen deposits could be detected
in NEMO-deficient hepatocytes, compared to evenly dis-
tributed small areas of glycogen deposition in control livers
(Figures 3G and 3H). Along with increased intracellular
deposition of glycogen, NEMOLPC-KO mice displayed a de-
crease in spontaneous serum glucose values compared to
control mice (Figure 3I), whereas neither serum lipid levels
nor serum insulin levels were elevated in these mice
(Figure S4). These findings argue for a defect in hepatic
glycogenolysis in NEMOLPC-KO mice. It has been demon-
strated previously that pharmacological inhibition of gly-
cogenolysis in rats results in a stimulation of intrahepatic
fat synthesis and development of hepatic steatosisFigure 3. Spontaneous Hepatitis and
Metabolic Alterations in NEMOLPC-KO
Mice at 8 Weeks of Age
(A and B) Histological analysis of liver sections
from 8-week-old control (A) and NEMOLPC-KO
(B) mice reveal infiltration of mononuclear cells
in the liver of NEMOLPC-KO mice.
(C) Oil red O staining of liver sections from
8-week-old NEMOLPC-KO mice shows areas
of focal lipid accumulation.
(D–F) Representative H/E-stained histological
sections of livers from 8-week-old mice show
strong anisokaryosis (indicated by arrows)
but normal nuclear-to-cytoplasmic ratio as
signs of large-cell dysplasia in NEMOLPC-KO
mice (E) in contrast to normal histology in
control (D) and IKK2LPC-KO (F) mice.
(G and H) Representative electron microscopic
(EM) pictures of mitochondria in the liver of
control (G) and NEMOLPC-KO mice (H). Notice
the swelling and pleiomorphic form with strong
reduction in mitochondrial crests along with
large areas of abnormal glycogen deposition
in NEMOLPC-KO mice.
(I) Venous blood was drawn from six nonstarved
mice per group between 10 a.m. and 11 a.m.
from NEMOLPC-KO and control mice. Spontane-
ous serum glucose was measured as indicated.
Results are expressed as mean; error bars
indicate standard error of the mean (SEM).c.
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Conditional Deletion of NEMO Causes Liver TumorsFigure 4. Enhanced Cell Death and Cell-Cycle Activation in NEMOLPC-KO Mice
(A) Circulating ALT levels in serum from mice at 3 weeks and 8 weeks of age as indicated. *p < 0.05 compared to control mice. **p < 0.01 compared to
control and IKK2LPC-KO mice. Results are expressed as mean; error bars indicate SEM.
(B) Representative TUNEL staining of liver sections from 8-week-old male mice showing increased apoptosis in NEMOLPC-KO mice compared to
wild-type and IKK2LPC-KO mice.
(C) Immunoblot analysis on whole-liver extracts from 8-week-old NEMOLPC-KO, IKK2LPC-KO, and wild-type control mice using an antibody that
specifically detects the cleaved form of caspase-3 or tubulin as loading control.
(D) Representative BrdU staining on liver samples from 8-week-old NEMOLPC-KO, IKK2LPC-KO, and control mice that had been pulse labeled with BrdU
every 8 hr for 2 days prior to sacrificing.
(E) Immunoblot analysis on whole-liver extracts from 8-week-old mice using antibodies against Cyclin D1, PCNA, or tubulin as loading control.
(F and G) Immunohistochemical staining of liver sections from 8-week-old NEMOLPC-KO and control mice revealing strong activation of hepatic
progenitor cells (oval cells) in NEMOLPC-KO mice (F).
(H) Representative EM picture of an oval cell in NEMOLPC-KO. The arrow indicates the basal membrane as one of the specific features of a progenitor
cell in the liver.(Bandsma et al., 2001; Herling et al., 1999), suggesting that
a disturbance in hepatic carbohydrate metabolism might
be the initial event in the development of fatty liver disease
in NEMOLPC-KO mice.
Increased Hepatocyte Apoptosis and Regeneration
in the Liver of NEMOLPC-KO Mice
The finding that young NEMOLPC-KO mice show liver in-
flammation and steatosis prompted us to examine further
the early stages of this phenotype. At 3 weeks of age,
NEMOLPC-KO mice displayed a considerable elevation of
alanine aminotransferase (ALT) in the serum, indicating
the presence of hepatocyte damage, and ALT levels
were further increased at 8 weeks (Figure 4A). Further-
more, 8-week-old NEMOLPC-KO mice showed an in-
creased number of TUNEL-positive cells and activation
of caspase-3 in the liver compared to control and
IKK2LPC-KO animals (Figures 4B and 4C). Therefore, in-
creased apoptotic death of hepatocytes occurs sponta-Cneously in the liver of NEMOLPC-KO mice and is already ap-
parent at 3 weeks of age. In parallel with increased cell
death, we detected increased proliferation in the liver of
NEMOLPC-KO mice, as demonstrated by an elevated num-
ber of cells incorporating BrdU and by the upregulation of
Cyclin D1 and PCNA expression, two markers indicating
cell-cycle activation (Figures 4D–4E).
Chronic inflammation can impose restrictions on the
proliferative capacity of hepatocytes, leading to impaired
liver regeneration (Marshall et al., 2005). Oval cells are
bipotential hepatic progenitor cells with a long-term repo-
pulating potential that are activated in many chronic liver
diseases where increased hepatocyte loss needs to be
compensated by enhanced liver regeneration (Alison and
Lovell, 2005). Immunohistochemical staining revealed
strong activation of oval cells in the liver of 8-week-old
NEMOLPC-KO mice compared to controls (Figures 4F and
4G). Furthermore, EM analysis confirmed the increased
presence of activated progenitor cells in the liver of theseancer Cell 11, 119–132, February 2007 ª2007 Elsevier Inc. 123
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that chronic spontaneous hepatocyte death induces
a regenerative response with compensatory hepatocyte
proliferation and activation of hepatic progenitor cells in
NEMOLPC-KO mice, which may form the basis for the
development of liver cancer in these mice.
Deletion of NEMO Completely Blocks NF-kB
Activation and Sensitizes the Liver
to LPS-Induced Toxicity
The finding that NEMOLPC-KO but not IKK2LPC-KO mice de-
velop spontaneous liver disease and cancer prompted us
to investigate further the effects of NEMO versus IKK2 de-
letion in the liver, in particular with regards to NF-kB activa-
tion and protection from cytokine-induced toxicity. TNF
administration in vivo failed to induce NF-kB activation in
the liver of adult NEMOLPC-KO mice (Figure 5A). Moreover,
NEMOLPC-KO mice showed complete inhibition of NF-kB
activation upon injection of lipopolysaccharide (LPS)
(Figure 5B), which acts as a potent inducer of endogenous
TNF and other cytokines (Pasparakis et al., 1996; Pfeffer
et al., 1993). Under the same treatment, considerable
NF-kB activation was detected in the liver of IKK2LPC-KO
mice, showing that Ikk2 deletion does not result in com-
plete NF-kB inhibition in response to LPS (Figure 5C).
TNF stimulation of primary hepatocytes confirmed that
NEMO knockout blocks completely IkBa degradation,
while substantial IkBa degradation occurs in the absence
of IKK2 (Figure 5D). Therefore, NEMO ablation leads to
complete inhibition of NF-kB activation by LPS and TNF
in the liver, while considerable NF-kB activity is retained
in the absence of IKK2, presumably due to compensatory
signaling by IKK1.
Consistent with the lackof NF-kB activation,NEMOLPC-KO
mice developed massive hepatocyte apoptosis and ful-
minant liver failure upon LPS challenge (Figures 5E and
5F), demonstrating that NF-kB activation is essential to
protect the adult liver from TNF-induced apoptosis. LPS
administration did not cause substantial liver damage
and hepatocyte apoptosis in the liver of IKK2LPC-KO mice
(Figures 5E and 5F), consistent with the considerable
induction of NF-kB activity in the absence of IKK2. This
finding is in accordance with previous results, obtained
using either the same IKK2LPC-KO mice employed in this
report (Luedde et al., 2005) or a different hepatocyte-
specific IKK2 knockout strain (Maeda et al., 2003), show-
ing that deletion of IKK2 in liver parenchymal cells does
not sensitize the liver to LPS/TNF challenge. Taken to-
gether, these results demonstrate that deletion of
NEMO, but not IKK2, completely blocks NF-kB activa-
tion in hepatocytes and uncovers the essential role of
NF-kB to protect the adult mouse liver from TNF-induced
toxicity.
Increased Cytokine Expression, JNK Activation,
and Impaired Antiapoptotic Gene Expression
in NEMOLPC-KO Mice
To further investigate the role of inflammation in the devel-
opment of hepatitis in NEMOLPC-KO, mice we analyzed the124 Cancer Cell 11, 119–132, February 2007 ª2007 Elsevier Incexpression of proinflammatory mediators in the liver. We
found upregulation of TNF, IL-6, IL-1b, and RANTES in
the liver of NEMOLPC-KO mice (Figure 6A), suggesting
that increased expression of proinflammatory cytokines
and chemokines is implicated in the development of hepa-
titis in thesemice. These cytokinesare likely tobeproduced
by Kupffer cells, which are the main source of cytokines in
the liver (Ramadori and Armbrust, 2001). As Kupffer cells
are not targeted by the Alfp-Cre transgene (Kellendonk
et al., 2000; Luedde et al., 2005), they express NEMO and
have full capacity to activate NF-kB and produce pro-
inflammatory mediators. Consistently, immunohistochem-
ical analysis identified nonparenchymal liver cells as the
major source of TNF in NEMOLPC-KO mice (Figure 6B). He-
patocyte death activates Kupffer cells in models of chronic
liver injury (Canbay et al., 2005), suggesting that increased
spontaneous death of NF-kB-deficient parenchymal cells
in NEMOLPC-KO mice might induce the expression of cyto-
kines and chemokines from Kupffer cells.
We aimed to analyze further the molecular mechanisms
that lead to spontaneous hepatocyte death in NEMOLPC-KO
mice. JNK activation has been suggested as an impor-
tant mediator of TNF-induced cell death in the liver
(Schwabe and Brenner, 2006). Analysis of JNK phosphor-
ylation revealed constitutive JNK activation in the liver of
NEMOLPC-KO, but not in control or IKK2LPC-KO mice
(Figure 6C), suggesting that the increased cell death of
NEMO-deficient hepatocytes might be caused by persis-
tent JNK activity. Analysis of the expression of NF-kB tar-
get genes known to have antiapoptotic and antioxidant
functions revealed that XIAP, cIAP-1, GADD45a, SOD1,
and SOD2 were downregulated in the liver of NEMOLPC-KO
mice (Figure 6D). In contrast, the expression of Bax,
a Bcl-2 family member with proapoptotic function (Fes-
tjens et al., 2004), was upregulated in the NEMO-deficient
liver (Figure 6D). Moreover, immunoblot analysis showed
that the expression of Bcl-2 was unaffected, while the
majority of Bax protein was processed into a lower-molec-
ular-weight form in the liver of NEMOLPC-KO mice (Fig-
ure 6E). Previous studies suggested that inhibition of NF-
kB leads to increased expression of Bax (Bentires-Alj
et al., 2001), and that an N-terminally cleaved 18 kDa
form of Bax is a more potent inducer of cell death acting in-
dependently of the protecting function of Bcl-2 (Gao and
Dou, 2000). Furthermore, oxidative stress-induced apo-
ptosis in hepatocytes can lead to N-terminal Bax cleavage
(Tamura et al., 2003), again pointing toward an important
role for oxidative stress as mediator of cell death in
NEMOLPC-KO mice.
Antioxidant Treatment Prevents the Development
of Steatohepatitis in NEMOLPC-KO Mice
To evaluate the contribution of oxidative stress to the path-
ogenesis of liver disease in NEMOLPC-KO mice, we placed
a group of mice on a diet supplemented with the antioxi-
dant butylated hydroxyanisole (BHA) starting at 4 weeks
of age and followed them until they were 10 weeks old.
NEMOLPC-KO mice on the BHA diet showed an immediate
and striking improvement of the hepatitis phenotype, as.
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Conditional Deletion of NEMO Causes Liver TumorsFigure 5. Ablation of NEMO Specifically in Liver Parenchymal Cells Blocks NF-kB Activation and Sensitizes the Liver to
LPS-Induced Toxicity
(A) Nuclear protein extracts were prepared from the liver of NEMOLPC-KO and wild-type mice at the indicated time points after TNF stimulation and were
subjected to a gel retardation assay with an NF-kB consensus probe to measure NF-kB DNA-binding activity as described under Experimental Proce-
dures. In lanes 8 and 9, antibodies for the NF-kB subunits p50 or p65 were added as indicated to identify the respective NF-kB dimers by supershifting.
(B and C) IkBa phosphorylation and degradation were assessed by immunoblot analysis of liver protein extracts from NEMOLPC-KO (B), IKK2LPC-KO (C),
and their respective littermate control mice at the indicated time points after LPS administration using antibodies against phosphorylated IkBa, total
IkBa, or tubulin as loading control.
(D) Primary hepatocytes from the indicated mouse lines were stimulated with murine recombinant TNF for the indicated time points, and degradation
of IkBa was assessed by immunoblot.
(E) Liver damage 10 hr after LPS stimulation in NEMOLPC-KO, IKK2LPC-KO, and control mice (WT) was assessed by analysis of serum ALT levels.
*p < 0.01 compared to control and IKK2LPC-KO mice. Results are expressed as mean; error bars indicate SEM.
(F) Representative TUNEL staining of liver sections 10 hr after LPS stimulation showing massive apoptosis in NEMOLPC-KO but not in IKK2LPC-KO or
wild-type mice. Nuclei were visualized by DAPI staining.shown by a drop of serum ALT to almost normal levels
(Figure 7A). Furthermore, histological analysis of the liver
from these mice showed a significant improvement of
the pathological changes with a strong reduction of spon-
taneous hepatocyte apoptosis and also of inflammation
and anisokaryosis compared to untreated NEMOLPC-KO
mice (Figures 7B and 7C). In addition, BHA treatment ledCanto a strong reduction in JNK activation and normalized
the increased expression of Bax in the liver of NEMOLPC-KO
mice (Figures 7D–7E). Electron microscopy revealed a
normalization of mitochondrial structure along with signs
of increased mitochondrial biogenesis as shown by
dividing mitochondria, and also normalization of glycogen
distribution in the liver from BHA-treated mice (Figure 7F).cer Cell 11, 119–132, February 2007 ª2007 Elsevier Inc. 125
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Conditional Deletion of NEMO Causes Liver TumorsFigure 6. Increased Cytokine Expression, JNK Activation, and Impaired Antiapoptotic Gene Transcription in NEMOLPC-KO Mice
(A) Quantitative RT-PCR analysis of cytokine mRNA levels in the liver of 8-week-old mice. Results are expressed as mean; error bars indicate SEM.
(B) Immunohistochemical staining for TNF reveals TNF expression mainly in nonparenchymal liver cells in NEMOLPC-KO mice.
(C) Liver protein extracts from 8-week-old NEMOLPC-KO and control mice were prepared and subjected to immunoblot using antibodies detecting
either the phosphorylated or the total forms of p46 and p54 JNK.
(D) Quantitative RT-PCR analysis of the mRNA levels of the indicated genes in the liver of 5-week-old NEMOLPC-KO and control mice. Values are
mean ± SEM from three mice per group.
(E) Immunoblot analysis of liver protein extracts from 8-week-old NEMOLPC-KO and control mice using antibodies against Bax, Bcl-2, or tubulin as
loading control. The Bax antibody detects two isoforms of Bax, with a shorter, cleaved form as the predominant form in NEMOLPC-KO mice.Furthermore, no signs of steatosis or increased lipid
deposition were seen after 6 weeks of BHA treatment
(Figure 7G). These findings argue that the development
of steatosis is a secondary event caused by oxidative
stress-dependent mechanisms. Therefore, treatment with
the antioxidant BHA normalized all aspects of the liver
disease developing in NEMOLPC-KO mice, demonstrating
that increased oxidative stress plays a critical role in the
induction of sustained JNK activation leading to hepato-
cyte death and steatohepatitis in this model.
The Development of Steatohepatitis in NEMOLPC-KO
Mice Depends on FADD-Mediated Hepatocyte
Apoptosis
The increased expression of cytokines such as TNF, which
are known to induce apoptosis in liver parenchymal
cells under certain circumstances (Luedde et al., 2002),
prompted us to investigate whether the increased oxi-126 Cancer Cell 11, 119–132, February 2007 ª2007 Elsevierdative stress, JNK activity, and cell death in the liver of
NEMOLPC-KO mice is induced by death-receptor signal-
ing. FADD is an adaptor molecule that is essential for cas-
pase-8 activation and induction of cell death downstream
of TNFRI and Fas (Strasser and Newton, 1999). To investi-
gate in vivo the role of FADD in the induction of liver
apoptosis, we generated mice with liver parenchymal
cell-specific FADD knockout (FADDLPC-KO) by crossing
mice with a loxP-flanked Fadd allele (G.v.L. and M.P, un-
published data) with theAlfp-Cre transgenic mice. In order
to test whether the increased hepatocyte death in the
NEMOLPC-KO mice depends on death receptor-induced
apoptosis, we interbred the NEMOLPC-KO mice with the
FADDLPC-KO mice to generate mice lacking both NEMO
and FADD in the liver (NEMO/FADDLPC-KO) (Figure 8A).
The double NEMO/FADDLPC-KO mice were protected
from LPS-induced hepatocyte apoptosis compared to
NEMOLPC-KO mice (Figures 8B–8D), demonstrating thatInc.
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Development of Hepatitis and NASH in
NEMOLPC-KO Mice
(A) Serum ALT levels in a group of NEMOLPC-KO
mice receiving a diet supplemented with 0.7%
BHA starting at 4 weeks of age compared with
NEMOLPC-KO and control mice on a normal
diet. *p < 0.05 compared to NEMOLPC-KO
mice on normal diet. Results are expressed
as mean; error bars indicate SEM.
(B) Representative H&E staining (upper panel)
and TUNEL staining (lower panel) from
NEMOLPC-KO mice on a diet supplemented
with BHA at 10 weeks of age. (Compare to
NEMOLPC-KO mice on normal diet at the same
age [Figures 3E and 4B].)
(C) Immunoblot analysis of liver extracts from
10-week-old mice using antibodies against
cleaved caspase-3 or tubulin as loading control.
(D) Immunoblot analysis with antibodies de-
tecting specifically the phosphorylated form
of JNK or total JNK on whole-liver extracts
from NEMOLPC-KO mice on normal diet (lane1)
and NEMOLPC-KO mice on BHA diet (lanes 2
and 3).
(E) Quantitative RT-PCR analysis of Bax mRNA
expression in livers from control mice,
NEMOLPC-KO mice on normal diet, and
NEMOLPC-KO mice on BHA diet. Results are
expressed as mean; error bars indicate SEM.
(F) Representative EM analysis of mitochondria
in livers from NEMOLPC-KO mice treated for
6 weeks with BHA, showing normalization of
mitochondrial structure and normal distribution
of glycogen. The arrow indicates an area of
mitochondrial division as a sign of biogenesis
of mitochondria upon antioxidant treatment.
(G) Representative oil red O staining on a liver
slide from 10-week-old NEMOLPC-KO mice
treated for 6 weeks with the antioxidant BHA.
Note that no focal lipid accumulation was
detected in the mice at this stage (compare
to Figure 3C).FADD deficiency blocks death receptor-induced killing
of NF-kB-deficient hepatocytes. Although hepatocytes
lacking both NEMO and FADD were protected from
apoptosis, we detected sustained JNK activation in the
liver of double NEMO/FADDLPC-KO mice upon LPS
injection (Figure S5A). These experiments provide an in
vivo genetic proof that FADD-dependent caspase-8
activation is essential for the induction of cell death
downstream of oxidative stress-induced sustained JNK
activation.
We then analyzed whether FADD deficiency also neu-
tralized the spontaneous hepatocyte apoptosis and
hepatitis in NEMOLPC-KO mice. Indeed, double NEMO/
FADDLPC-KO mice showed strongly decreased spontane-
ous serum ALT values compared to NEMOLPC-KO mice
(Figure 8E), together with a clear improvement in liver his-
tology marked by the complete disappearance of inflam-
mation, decreased spontaneous apoptosis, and absenceCaof anisokaryosis at the age of 8 weeks (Figures 8F and
8G). Therefore, the spontaneous hepatocyte cell death
and hepatitis in NEMOLPC-KO mice is caused by FADD-
dependent signaling downstream of death receptors
such as Fas and TNFRI. Despite the rescue of hepatocyte
apoptosis, double NEMO/FADDLPC-KO mice showed in-
creased spontaneous JNK activity in the liver similarly to
NEMOLPC-KO mice, in contrast to mice treated with BHA,
where the sustained JNK activation was abolished (Fig-
ure 8H). In addition to rescuing hepatocyte death, FADD
deficiency also inhibited the increased proliferation ob-
served in the liver of NEMOLPC-KO mice, as shown by the
reduced expression of cyclin D1 and PCNA in the liver of
double NEMO/FADDLPC-KO mice (Figure 8I). This finding
shows that the increased proliferation in the liver of
NEMOLPC-KO mice is a secondary event induced in re-
sponse to the death of hepatocytes. In addition, NEMO/
FADDLPC-KO mice at the age of 4 months did not showncer Cell 11, 119–132, February 2007 ª2007 Elsevier Inc. 127
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Conditional Deletion of NEMO Causes Liver TumorsFigure 8. Role of Death-Receptor Signaling in Hepatitis in NEMOLPC-KO Mice
(A) Efficient ablation of both NEMO and FADD in the liver of double NEMO/FADDLPC-KO mice, as shown by immunoblot of liver protein extracts with the
indicated antibodies.
(B) Representative TUNEL staining on liver slides from mice with the indicated genotypes 10 hr after LPS stimulation.
(C) Measurement of serum ALT levels 10 hr after LPS injection shows protection of NEMO/FADDLPC-KO mice from liver damage. *p < 0.01. Results are
expressed as mean; error bars indicate SEM.
(D) Immunoblot analysis on liver protein extracts from mice with the indicated genotypes at different time points after LPS treatment, using antibodies
detecting the cleaved form of caspase-3, both pro-caspase-8 and cleaved caspase-8, and tubulin as loading control.
(E) Measurement of serum ALT shows significantly reduced spontaneous liver injury in NEMO/FADDLPC-KO mice compared NEMOLPC-KO animals at
8 weeks of age. *p < 0.05 compared to NEMOLPC-KO mice. Results are expressed as mean; error bars indicate SEM.
(F) Representative H&E staining (upper panel) and TUNEL staining (lower panel) on slides of livers from mice at 8 weeks of age.
(G) Immunoblots on extracts from 8-week-old NEMOLPC-KO and NEMO/FADDLPC-KO mice using antibodies against cleaved caspase-3 or tubulin as
loading control.
(H) Immunoblots with antibodies detecting specifically the phosphorylated form of JNK or total JNK as loading control.
(I) Immunoblots using extracts from 8-week-old NEMOLPC-KO and NEMO/FADDLPC-KO mice with antibodies against cyclin D1, PCNA, and tubulin as
loading control.focal lipid accumulation, which was already apparent in
NEMOLPC-KO mice at the age of 8 weeks (Figure S5B).
This result suggests that the increased fat deposition in
the liver of NEMOLPC-KO mice is a secondary consequence
of the chronic hepatitis associated with inflammation and
oxidative stress, rather than a primary metabolic defect.
Taken together, these findings show that FADD-depen-
dent death of NEMO-deficient hepatocytes is an essential
upstream event that triggers the development of steatohe-
patitis in NEMOLPC-KO mice.128 Cancer Cell 11, 119–132, February 2007 ª2007 Elsevier InDISCUSSION
Here we show that ablation of NEMO/IKKg in liver paren-
chymal cells caused the spontaneous development of he-
patocellular carcinoma in mice. These findings revealed
a physiological function of NF-kB in protecting the liver
from cancer, identifying NEMO as a tumor suppressor in
the liver. The tumors developed in the context of chronic
hepatitis resembling human nonalcoholic fatty liver dis-
ease (NAFLD) and NASH. A link between NASH andc.
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though the extent of this association remains unclear
(Brunt, 2004; Farrell and Larter, 2006). Our findings that
steatotic hepatitis and HCC developed with 100% pene-
trance in NEMOLPC-KO mice show that the NASH-like hep-
atitis phenotype predisposes to liver carcinogenesis, sug-
gesting that also in humans NASH may constitute a critical
risk factor for HCC development. Given that NAFLD and
NASH are expected to account for an increasing percent-
age of chronic liver diseases leading to cirrhosis and liver
cancer in Western countries (Farrell and Larter, 2006),
the NEMOLPC-KO mice represent an animal model that
may be valuable to further characterize the molecular
mechanisms leading to cancer development in the context
of NASH.
Using genetic and pharmacological in vivo analysis, we
demonstrated that the FADD-mediated and oxidative
stress-dependent death of NF-kB-deficient hepatocytes
was the critical pathogenic step that triggered chronic liver
disease and cancer in this model. These results shed light
on the controversial discussion about the function of
NF-kB in the development of HCC and suggest the fol-
lowing model for the development of liver tumors in the
NEMOLPC-KO mice: NEMO-deficient hepatocytes undergo
apoptosis in response to FADD-mediated and oxidative
stress-dependent death-receptor signaling. Hepatocyte
death triggers inflammation and a regenerative response
in the liver with reactive proliferation of hepatocytes. In
this chronic state of liver inflammation, apoptosis, and re-
generation, hepatocytes proliferating under conditions of
increased oxidative stress may accumulate mutations
leading to dysplasia and eventually to tumor development.
Apoptosis is generally considered as a mechanism pre-
venting tumor development, and evasion of apoptotic
cell death is considered a classic cellular feature contribut-
ing to cancer (Hanahan and Weinberg, 2000). In this con-
text, NF-kB activation is generally considered as a survival
signal allowing tumor cells to escape apoptosis, and thus
NF-kB inhibition is expected to have antioncogenic ef-
fects. Our results, on the other hand, demonstrate that in
the liver NF-kB inhibition promotes hepatocarcinogenesis
by sensitizing hepatocytes to spontaneous apoptosis.
This apparent contradiction can be explained by the
unique features of the liver, which has the capacity to re-
generate upon injury through the compensatory prolifera-
tion of hepatocytes. Liver responses to injury are deter-
mined by the unique interplay between parenchymal and
nonparenchymal liver cells, with hepatocyte death induc-
ing activation of Kupffer cells that in turn produce cyto-
kines to promote regeneration. Therefore, in a tissue
such as the liver, susceptibility to apoptosis as seen in
the NEMOLPC-KO mouse may lead to a chronic state of
hepatocyte death and regenerative proliferation, which
constitutes a risk factor for cancer development.
Oval cells—hepatocyte progenitor cells located in the
periphery of the biliary tract—represent a constant source
to restore the pool of hepatocytes in the liver, and their
potential involvement in liver tumor development in both
humans and in animal models has recently raised increas-Cing interest (Alison and Lovell, 2005; Fang et al., 2004; Lib-
brecht et al., 2005). Furthermore, a recent study identified
a subtype of hepatocellular carcinomas related to hepatic
progenitor cells that was linked with a poor prognosis (Lee
et al., 2006). We found strong activation of oval cells in
NEMOLPC-KO mice, suggesting that the mobilization of
the stem-cell pool of the liver is critical to provide a con-
stant cellular source to compensate for the loss of paren-
chymal cells. However, at this stage it remains unclear
whether the tumors developing in the NEMO-deficient
livers are, at least in part, derived from progenitor cells.
Deletion of Ikk2 does not lead to spontaneous liver
pathology. IKK2 in contrast to NEMO is a kinase and
thus might have other substrates than IkBa, whereas
NEMO so far has only been linked to NF-kB activity, mean-
ing that loss of NEMO and IKK2 cannot be equated. How-
ever, our results suggest that the difference between the
NEMOLPC-KO and IKK2LPC-KO mice lies in the differential
effect of these two knockouts on inhibiting NF-kB
activation and antiapoptotic function. In contrast to
NEMOLPC-KO mice, IKK2LPC-KO animals are not sensitive
to LPS- or TNF-induced liver damage, showing that the
level of NF-kB inhibition achieved by Ikk2 deletion is not
sufficient to sensitize hepatocytes to cytokine-induced
toxicity. Therefore, a critical threshold of NF-kB activity de-
termines the ability of liver parenchymal cells to survive
during adult life, and inhibition of NF-kB below this thresh-
old, achieved here by deletion of NEMO, renders hepato-
cytes dramatically sensitive to death receptor-induced
apoptosis resulting in chronic hepatitis. Although the
ligand-receptor pair(s) that play a critical role in inducing
spontaneous hepatocyte apoptosis in NEMOLPC-KO mice
are not known at present, it is likely that hepatocyte death
is initiated by small amounts of cytokines produced nor-
mally in mice living in a nonsterile surrounding. These cyto-
kines may be expressed by innate immune cells that are
activated through Toll-like receptors in response to con-
tact with bacteria or bacterial products, which originate
from the large intestine and are transported to the liver
via the portal circulation, where they can activate hepatic
Kupffer cells to produce inflammatory cytokines such as
TNF (Enomoto et al., 2002). As the mice reported in this
study were not kept under germ-free conditions, it is pos-
sible that bacteria that are apparently not pathogenic for
wild-type or IKK2LPC-KO mice are transformed into in-
ducers of chronic liver disease and HCC in NEMOLPC-KO
mice due to the extreme sensitivity of NEMO-deficient
hepatocytes to cytokine-induced cell death. Future exper-
iments on germ-free animals will be required to address
experimentally this hypothesis.
Mutations in the X-linked humanNEMO gene cause two
distinct genetic diseases, hypohydrotic ectodermal dys-
plasia with immune deficiency (HED-ID) and incontinentia
pigmenti (IP), in humans (Courtois, 2005), but have not
been associated with liver cancer. HED-ID is caused by
hypomorphic NEMO mutations, which do not completely
abolish but rather reduce NF-kB activation, resulting in
impaired skin appendage development and severe im-
mune deficiency. The lack of a liver defect in HED-IDancer Cell 11, 119–132, February 2007 ª2007 Elsevier Inc. 129
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NF-kB and by the presence of the mutation in all cells, in
contrast to the NEMOLPC-KO mice, where NF-kB-deficient
hepatocytes are killed by cytokines expressed by cells ex-
pressing NEMO. IP is caused by mutations disrupting the
humanNEMO gene. Male IP patients die in utero, whereas
heterozygous female patients survive and display a range
of clinical phenotypes caused by the mosaic presence of
NEMO-deficient cells in multiple tissues. Liver complica-
tions are not usually reported in those female IP patients,
although there is one such report in the literature (Oberti
et al., 1997). The most likely explanation for this is that,
due to their extreme sensitivity to apoptosis, the NEMO-
deficient cells quickly disappear from the mosaic livers
and are replaced by wild-type cells. This is likely to happen
during embryonic development, based on results obtained
from Nemo knockout mouse models (Makris et al., 2000;
Rudolph et al., 2000; Schmidt-Supprian et al., 2000).
Therefore, adult IP patients would be expected to have
only NEMO-expressing hepatocytes and would not show
any liver phenotype. This hypothesis is strongly supported
by a case report about a female infant born to a mother
with IP and a father with hemophilia A, who showed a highly
skewed pattern of X inactivation and manifested both dis-
orders (Coleman et al., 1993).
The results reported in this study raise important con-
siderations for pharmacological therapies targeting the
IKK complex in human patients, which has been sug-
gested as a powerful approach to treat inflammatory and
other disorders (Burke, 2003). Our experiments show
that complete inhibition of IKK activity in hepatocytes
might be detrimental and might result in liver disease
and even liver cancer upon long-term treatment. This
might be particularly relevant for pharmacological inhibi-
tors that would target the regulatory function of NEMO
rather than the activity of IKK2. On the other hand, de-
pending on pharmacokinetic properties, pharmacological
inhibition of the IKK complex targeting all cells might lead
to a different outcome than our hepatocyte-specific ge-
netic approach, by neutralizing the expression of cyto-
kines from effector cells and thus eliminating the trigger
causing the death of NF-kB-deficient hepatocytes. In
any case, our findings highlight the need for extensive
research on the potential detrimental consequences of
long-term NF-kB inhibition.
EXPERIMENTAL PROCEDURES
Generation of Conditional Knockout Mice
for NEMO, IKK2, and NEMO/FADD
Mice carrying loxP-site-flanked (floxed [Fl]) Nemo (NemoFl) and Ikk2
alleles (Ikk2Fl) were described previously (Pasparakis et al., 2002;
Schmidt-Supprian et al., 2000). NemoFL and Ikk2FL mice were crossed
to Alfp-Cre transgenic mice (Kellendonk et al., 2000) to generate
a parenchymal liver cell-specific knockout of the respective gene
(NEMOLPC-KO and IKK2LPC-KO). NEMOLPC-KO mice were crossed toFaddFl
mice (G.V.L. and M.P., unpublished data) for a conditional double-
knockout of both Nemo and Fadd (NEMO/FADDLPC-KO) in liver paren-
chymal cells. In all experiments, littermates carrying the respective
loxP-flanked alleles but lacking expression of Cre recombinase were
used as wild-type (WT) controls. All animals received care according130 Cancer Cell 11, 119–132, February 2007 ª2007 Elsevier Incto institutional animal care committee guidelines. Animal procedures
were conducted in compliance with European, national, and institu-
tional guidelines and protocols. For antioxidant treatment, mice were
fed on a diet containing 0.7% BHA (Sigma) from 4 weeks of age until
sacrifice.
Liver Injury Models
Experiments were performed on male mice between 8 and 10 weeks of
age. Murine recombinant TNF (Nenci et al., 2006) or LPS (Sigma) were
administered i.p. at concentrations of 10 mg/kg (TNF) or 25 mg/10 g
(LPS). Alanine-aminotransferase (ALT) activities, serum cholesterol,
triglyceride, glucose, and insulin levels were measured by standard
procedures.
Immunoblot Analysis
Protein lysates were prepared from primary hepatocytes or liver
samples, separated by SDS-polyacrylamide gel electrophoresis
(PAGE), transferred to nitrocellulose, and analyzed by immunoblotting.
Membranes were probed with the following antibodies: anti-NEMO
(Nenci et al., 2006); anti-Tubulina (Sigma); anti-phospho-IkBa, anti-
JNK, anti-phospho-JNK, anti-cleaved-caspase3, and anti-Bax (Cell
Signaling); anti-FADD and anti-caspase-8 (Alexis); anti-cyclinD1 and
anti-IkBa (Santa Cruz); anti-IKK2 (Imgenex); and anti-PCNA (Bio-
source). As secondary antibodies, anti-rabbit-HRP, anti-mouse-HRP,
and anti-rat-HRP were used (Amersham). Primary hepatocytes were
isolated and cultured as described previously (Luedde et al., 2005).
Quantitative Real-Time PCR
Total RNA was purified from liver tissue using Trizol reagent (Invitro-
gen). Total RNA (1 mg) was used to synthesize cDNA using SuperScript
First-Strand Synthesis System (Invitrogen) and was resuspended in
100 ml of H2O. cDNA samples (5 ml) were used for real-time PCR, in
a total volume of 20 ml using SYBR Green Reagent (Finzyme) and
specific primers on a qPCR machine (Opticon 2, MJ Research Inc.).
Real-time PCR reactions were performed in triplicates. Primer se-
quences are available upon request. All values were normalized to
the level of ubiquitin mRNA.
Electromobility Shift Assay
Gel retardation assays were performed on nuclear extracts as
described previously (Schmidt-Supprian et al., 2000). DNA protein
complexes were resolved on a 6% polyacrylamide gel. A 32P-labeled
oligonucleotide representing an NF-kB consensus site (50-CGGGCTG
GGGATTCCCCATCTCGGTAC-30) was used as a probe. For super-
shifts, antibodies against p50 (sc-114X) and p65 (sc-109X) (Santa
Cruz Biotechnology) were used.
TUNEL Assay, BrdU Assay, Immunohistochemistry,
and Electron Microscopy
TUNEL test, BrdU assay, immunohistochemistry and electron micros-
copy were performed by standard procedures. For more detailed infor-
mation, see the Supplemental Experimental Procedures.
Statistics
Results in Figure S4 are expressed as mean ± SD, whereas error bars in
all other figures indicate ±standard error of the mean (SEM). Statistical
significance between experimental groups was assessed using an
unpaired two-sample Student’s t test.
Supplemental Data
The Supplemental Data include Supplemental Experimental Proce-
dures and five supplemental figures and can be found with this
article online at http://www.cancercell.org/cgi/content/full/11/2/119/
DC1/..
Cancer Cell
Conditional Deletion of NEMO Causes Liver TumorsACKNOWLEDGMENTS
We wish to thank G. Schu¨tz for the Alfp-Cre mice and C. Libbert for re-
combinant TNF. We thank T. Gillis, T. Tropartz and C. Uthoff-Hachen-
berg for technical assistance and D. Tosh, M. Lu¨dde, V. Desmet, C.
Netzer and the members of the Pasparakis lab for valuable discus-
sions. This work was supported by EMBL, the University of Cologne
and by EU-FP6 grants MUGEN (LSHG-CT-2005-005203) and IMDEMI
(MRTN-CT04-005632) to M.P. T.L. was supported by a postdoctoral
fellowship from the Schering Foundation Berlin/Germany, Science
Office.
Received: August 15, 2006
Revised: November 2, 2006
Accepted: December 5, 2006
Published: February 12, 2007
REFERENCES
Alison, M.R., and Lovell, M.J. (2005). Liver cancer: The role of stem
cells. Cell Prolif. 38, 407–421.
Bandsma, R.H., Wiegman, C.H., Herling, A.W., Burger, H.J., ter
Harmsel, A., Meijer, A.J., Romijn, J.A., Reijngoud, D.J., and Kuipers,
F. (2001). Acute inhibition of glucose-6-phosphate translocator activity
leads to increased de novo lipogenesis and development of hepatic
steatosis without affecting VLDL production in rats. Diabetes 50,
2591–2597.
Beg, A.A., Sha, W.C., Bronson, R.T., Ghosh, S., and Baltimore, D.
(1995). Embryonic lethality and liver degeneration in mice lacking the
RelA component of NF-kB. Nature 376, 167–170.
Bentires-Alj, M., Dejardin, E., Viatour, P., Van Lint, C., Froesch, B.,
Reed, J.C., Merville, M.P., and Bours, V. (2001). Inhibition of the
NF-kB transcription factor increases Bax expression in cancer cell
lines. Oncogene 20, 2805–2813.
Brunt, E.M. (2004). Nonalcoholic steatohepatitis. Semin. Liver Dis. 24,
3–20.
Burke, J.R. (2003). Targeting IkB kinase for the treatment of inflamma-
tory and other disorders. Curr. Opin. Drug Discov. Devel. 6, 720–728.
Canbay, A., Gieseler, R.K., Gores, G.J., and Gerken, G. (2005). The re-
lationship between apoptosis and non-alcoholic fatty liver disease: An
evolutionary cornerstone turned pathogenic. Z. Gastroenterol. 43,
211–217.
Chaisson, M.L., Brooling, J.T., Ladiges, W., Tsai, S., and Fausto, N.
(2002). Hepatocyte-specific inhibition of NF-kB leads to apoptosis
after TNF treatment, but not after partial hepatectomy. J. Clin. Invest.
110, 193–202.
Coffinier, C., Gresh, L., Fiette, L., Tronche, F., Schutz, G., Babinet, C.,
Pontoglio, M., Yaniv, M., and Barra, J. (2002). Bile system morphogen-
esis defects and liver dysfunction upon targeted deletion of HNF1b.
Development 129, 1829–1838.
Coleman, R., Genet, S.A., Harper, J.I., and Wilkie, A.O. (1993). Interac-
tion of incontinentia pigmenti and factor VIII mutations in a female with
biased X inactivation, resulting in haemophilia. J. Med. Genet. 30,
497–500.
Courtois, G. (2005). The NF-kB signaling pathway in human genetic
diseases. Cell. Mol. Life Sci. 62, 1682–1691.
Enomoto, N., Takei, Y., Hirose, M., Ikejima, K., Miwa, H., Kitamura, T.,
and Sato, N. (2002). Thalidomide prevents alcoholic liver injury in rats
through suppression of Kupffer cell sensitization and TNF-a produc-
tion. Gastroenterology 123, 291–300.
Fang, C.H., Gong, J.Q., and Zhang, W. (2004). Function of oval cells in
hepatocellular carcinoma in rats. World J. Gastroenterol. 10, 2482–
2487.
Farrell, G.C., and Larter, C.Z. (2006). Nonalcoholic fatty liver disease:
From steatosis to cirrhosis. Hepatology 43, S99–S112.CaFestjens, N., van Gurp, M., van Loo, G., Saelens, X., and Vandena-
beele, P. (2004). Bcl-2 family members as sentinels of cellular integrity
and role of mitochondrial intermembrane space proteins in apoptotic
cell death. Acta Haematol. 111, 7–27.
Gao, G., and Dou, Q.P. (2000). N-terminal cleavage of bax by calpain
generates a potent proapoptotic 18-kDa fragment that promotes
bcl-2-independent cytochrome C release and apoptotic cell death.
J. Cell. Biochem. 80, 53–72.
Ghosh, S., and Karin, M. (2002). Missing pieces in the NF-kB puzzle.
Cell Suppl. 109 (Suppl), S81–S96.
Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell
100, 57–70.
Herling, A.W., Burger, H., Schubert, G., Hemmerle, H., Schaefer, H.,
and Kramer, W. (1999). Alterations of carbohydrate and lipid interme-
diary metabolism during inhibition of glucose-6-phosphatase in rats.
Eur. J. Pharmacol. 386, 75–82.
International Working Party (1995). Terminology of nodular hepatocel-
lular lesions. Hepatology 22, 983–993.
Karin, M. (1999). How NF-kB is activated: The role of the IkB kinase
(IKK) complex. Oncogene 18, 6867–6874.
Karin, M., and Lin, A. (2002). NF-kB at the crossroads of life and death.
Nat. Immunol. 3, 221–227.
Kellendonk, C., Opherk, C., Anlag, K., Schutz, G., and Tronche, F.
(2000). Hepatocyte-specific expression of Cre recombinase. Genesis
26, 151–153.
Kojiro, M., and Roskams, T. (2005). Early hepatocellular carcinoma and
dysplastic nodules. Semin. Liver Dis. 25, 133–142.
Lavon, I., Goldberg, I., Amit, S., Landsman, L., Jung, S., Tsuberi, B.Z.,
Barshack, I., Kopolovic, J., Galun, E., Bujard, H., and Ben Neriah, Y.
(2000). High susceptibility to bacterial infection, but no liver dysfunc-
tion, in mice compromised for hepatocyte NF-kB activation. Nat.
Med. 6, 573–577.
Lee, J.S., Heo, J., Libbrecht, L., Chu, I.S., Kaposi-Novak, P., Calvisi,
D.F., Mikaelyan, A., Roberts, L.R., Demetris, A.J., Sun, Z., et al.
(2006). A novel prognostic subtype of human hepatocellular carcinoma
derived from hepatic progenitor cells. Nat. Med. 12, 410–416.
Li, Q., Van Antwerp, D., Mercurio, F., Lee, K.F., and Verma, I.M.
(1999a). Severe liver degeneration in mice lacking the IkB kinase 2
gene. Science 284, 321–325.
Li, Z.W., Chu, W., Hu, Y., Delhase, M., Deerinck, T., Ellisman, M.,
Johnson, R., and Karin, M. (1999b). The IKKb subunit of IkB kinase
(IKK) is essential for nuclear factor kB activation and prevention of
apoptosis. J. Exp. Med. 189, 1839–1845.
Libbrecht, L., Craninx, M., Nevens, F., Desmet, V., and Roskams, T.
(2001). Predictive value of liver cell dysplasia for development of hepa-
tocellular carcinoma in patients with non-cirrhotic and cirrhotic chronic
viral hepatitis. Histopathology 39, 66–73.
Libbrecht, L., Desmet, V., and Roskams, T. (2005). Preneoplastic
lesions in human hepatocarcinogenesis. Liver Int. 25, 16–27.
Luedde, T., Assmus, U., Wustefeld, T., Meyer zu Vilsendorf, A., Ros-
kams, T., Schmidt-Supprian, M., Rajewsky, K., Brenner, D.A., Manns,
M.P., Pasparakis, M., and Trautwein, C. (2005). Deletion of IKK2 in
hepatocytes does not sensitize these cells to TNF-induced apoptosis
but protects from ischemia/reperfusion injury. J. Clin. Invest. 115, 849–
859.
Luedde, T., Liedtke, C., Manns, M.P., and Trautwein, C. (2002). Losing
balance: Cytokine signaling and cell death in the context of hepatocyte
injury and hepatic failure. Eur. Cytokine Netw. 13, 377–383.
Maeda, S., Chang, L., Li, Z.W., Luo, J.L., Leffert, H., and Karin, M.
(2003). IKKb is required for prevention of apoptosis mediated by cell-
bound but not by circulating TNFa. Immunity 19, 725–737.
Maeda, S., Kamata, H., Luo, J.L., Leffert, H., and Karin, M. (2005). IKKb
couples hepatocyte death to cytokine-driven compensatory prolifera-
tion that promotes chemical hepatocarcinogenesis. Cell 121, 977–990.ncer Cell 11, 119–132, February 2007 ª2007 Elsevier Inc. 131
Cancer Cell
Conditional Deletion of NEMO Causes Liver TumorsMakris, C., Godfrey, V.L., Krahn-Senftleben, G., Takahashi, T., Rob-
erts, J.L., Schwarz, T., Feng, L., Johnson, R.S., and Karin, M. (2000).
Female mice heterozygous for IKKg/NEMO deficiencies develop
a dermatopathy similar to the human X-linked disorder incontinentia
pigmenti. Mol. Cell 5, 969–979.
Marshall, A., Rushbrook, S., Davies, S.E., Morris, L.S., Scott, I.S.,
Vowler, S.L., Coleman, N., and Alexander, G. (2005). Relation between
hepatocyte G1 arrest, impaired hepatic regeneration, and fibrosis in
chronic hepatitis C virus infection. Gastroenterology 128, 33–42.
Motola-Kuba, D., Zamora-Valdes, D., Uribe, M., and Mendez-San-
chez, N. (2006). Hepatocellular carcinoma. An overview. Ann. Hepatol.
5, 16–24.
Nenci, A., Huth, M., Funteh, A., Schmidt-Supprian, M., Bloch, W.,
Metzger, D., Chambon, P., Rajewsky, K., Krieg, T., Haase, I., and
Pasparakis, M. (2006). Skin lesion development in a mouse model of
incontinentia pigmenti is triggered by NEMO deficiency in epidermal
keratinocytes and requires TNF signaling. Hum. Mol. Genet. 15, 531–
542.
Oberti, F., Rifflet, H., Flejou, J.F., Leclech, C., Belghiti, J., Rousselet,
M.C., and Cales, P. (1997). [Association of hepatic adenomatosis
and hepatoportal sclerosis in a woman with incontinentia pigmenti].
Gastroenterol. Clin. Biol. 21, 147–151.
Okuda, K. (2000). Hepatocellular carcinoma. J. Hepatol. 32, 225–237.
Pahl, H.L. (1999). Activators and target genes of Rel/NF-kB transcrip-
tion factors. Oncogene 18, 6853–6866.
Pasparakis, M., Alexopoulou, L., Episkopou, V., and Kollias, G. (1996).
Immune and inflammatory responses in TNFa-deficient mice: A critical
requirement for TNFa in the formation of primary B cell follicles, follic-
ular dendritic cell networks and germinal centers, and in the maturation
of the humoral immune response. J. Exp. Med. 184, 1397–1411.
Pasparakis, M., Courtois, G., Hafner, M., Schmidt-Supprian, M.,
Nenci, A., Toksoy, A., Krampert, M., Goebeler, M., Gillitzer, R., Israel,
A., Krieg, T., Rajewsky, K., and Haase, I. (2002). TNF-mediated inflam-
matory skin disease in mice with epidermis-specific deletion of IKK2.
Nature 417, 861–866.132 Cancer Cell 11, 119–132, February 2007 ª2007 Elsevier InPfeffer, K., Matsuyama, T., Kundig, T.M., Wakeham, A., Kishihara, K.,
Shahinian, A., Wiegmann, K., Ohashi, P.S., Kronke, M., and Mak, T.W.
(1993). Mice deficient for the 55 kd tumor necrosis factor receptor are
resistant to endotoxic shock, yet succumb to L. monocytogenes infec-
tion. Cell 73, 457–467.
Pikarsky, E., Porat, R.M., Stein, I., Abramovitch, R., Amit, S., Kasem,
S., Gutkovich-Pyest, E., Urieli-Shoval, S., Galun, E., and Ben Neriah,
Y. (2004). NF-kB functions as a tumour promoter in inflammation-
associated cancer. Nature 431, 461–466.
Ramadori, G., and Armbrust, T. (2001). Cytokines in the liver. Eur. J.
Gastroenterol. Hepatol. 13, 777–784.
Rudolph, D., Yeh, W.C., Wakeham, A., Rudolph, B., Nallainathan, D.,
Potter, J., Elia, A.J., and Mak, T.W. (2000). Severe liver degeneration
and lack of NF-kB activation in NEMO/IKKg-deficient mice. Genes
Dev. 14, 854–862.
Schmidt-Supprian, M., Bloch, W., Courtois, G., Addicks, K., Israel, A.,
Rajewsky, K., and Pasparakis, M. (2000). NEMO/IKKg-deficient mice
model incontinentia pigmenti. Mol. Cell 5, 981–992.
Schwabe, R.F., and Brenner, D.A. (2006). Mechanisms of liver injury. I.
TNF-a-induced liver injury: Role of IKK, JNK, and ROS pathways. Am.
J. Physiol. Gastrointest. Liver Physiol. 290, G583–G589.
Sherman, M. (2005). Hepatocellular carcinoma: Epidemiology, risk
factors, and screening. Semin. Liver Dis. 25, 143–154.
Strasser, A., and Newton, K. (1999). FADD/MORT1, a signal trans-
ducer that can promote cell death or cell growth. Int. J. Biochem.
Cell Biol. 31, 533–537.
Tamura, H., Ohtsuru, A., Kamohara, Y., Fujioka, H., Yanaga, K.,
Kanematsu, T., and Yamashita, S. (2003). Bax cleavage implicates
caspase-dependent H2O2-induced apoptosis of hepatocytes. Int. J.
Mol. Med. 11, 369–374.
Tanaka, M., Fuentes, M.E., Yamaguchi, K., Durnin, M.H., Dalrymple,
S.A., Hardy, K.L., and Goeddel, D.V. (1999). Embryonic lethality, liver
degeneration, and impaired NF-kB activation in IKK-b-deficient
mice. Immunity 10, 421–429.c.
